A 2026 study described the acquired resistance pathway to KRAS G12C inhibitors in non-small cell lung cancer, identifying the AURKA/PHB2 signaling axis as a central driver. The authors reported that targeting or interrupting this axis could inform new combination approaches to counter resistance. By focusing on a named signaling route rather than a broad resistance category, the research aims to convert mechanistic understanding into actionable therapeutic hypotheses. The work also underscores how resistance emerges through reproducible pathway rewiring. For translational teams, the immediate implication is to evaluate whether AURKA and PHB2-linked strategies can resensitize resistant models or improve outcomes in clinical settings.